The importance of weight management in type 2 diabetes mellitus

被引:242
作者
Wilding, J. P. H. [1 ]
机构
[1] Aintree Univ Hosp NHS Fdn Trust, Liverpool L9 7AL, Merseyside, England
关键词
LIFE-STYLE INTERVENTION; CARDIOVASCULAR RISK-FACTORS; OBSTRUCTIVE SLEEP-APNEA; GASTRIC BYPASS-SURGERY; BARIATRIC SURGERY; FOLLOW-UP; OBESE-PATIENTS; GLYCEMIC CONTROL; GLUCOSE-TOLERANCE; MEDICAL THERAPY;
D O I
10.1111/ijcp.12384
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe obesity epidemic is driving the increased prevalence of type 2 diabetes mellitus (T2DM), and the vast majority of patients with T2DM are overweight or obese. Excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2DM. AimsTo review evidence about effects of weight loss in pre-diabetes and established T2DM. ResultsIn prediabetes, weight loss has been shown to delay the onset or decrease the risk of T2DM, while in established T2DM weight loss has been shown to improve glycaemic control, with severe calorie restriction even reversing the progression of T2DM. Observational studies support the reduction in cardiovascular risk factors following weight loss in patients with T2DM. However, data from the randomised Look AHEAD trial revealed intensive weight loss interventions did not reduce the rate of cardiovascular events in overweight or obese adults with T2DM, and secondary analyses of other large cardiovascular outcomes trials have also been inconclusive. However, besides cardiovascular risk, other documented benefits of weight loss in T2DM include improvements in quality of life, mobility, and physical and sexual function. ConclusionsPhysicians should encourage weight loss in all overweight patients with or at risk of T2DM, and should consider the impact on weight when choosing the most appropriate glucose-lowering therapies for these patients.
引用
收藏
页码:682 / 691
页数:10
相关论文
共 86 条
[1]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2]  
[Anonymous], 1990, METABOLISM, V39, P905, DOI 10.1016/0026-0495(90)90299-R
[3]  
[Anonymous], AM DIAB ASS 71 SCI S
[4]  
[Anonymous], WEIGHT LOSS DOES NOT
[5]  
[Anonymous], 2013, BMJ-BRIT MED J, DOI DOI 10.1136/bmj.f1515
[6]  
[Anonymous], EVID BASED MED
[7]  
[Anonymous], COCHRANE DATABASE SY
[8]   Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].
Astrup, A. ;
Carraro, R. ;
Finer, N. ;
Harper, A. ;
Kunesova, M. ;
Lean, M. E. J. ;
Niskanen, L. ;
Rasmussen, M. F. ;
Rissanen, A. ;
Rossner, S. ;
Savolainen, M. J. ;
Van Gaal, L. .
INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :843-854
[9]   A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin [J].
Berne, C .
DIABETIC MEDICINE, 2005, 22 (05) :612-618
[10]   Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels - A meta-analysis of 21 cohort studies including more than 300,000 persons [J].
Bogers, Rik P. ;
Bemelmans, Wanda J. E. ;
Hoogenveen, Rudolf T. ;
Boshuizen, Hendriek C. ;
Woodward, Mark ;
Knekt, Paul ;
van Dam, Rob M. ;
Hu, Frank B. ;
Visscher, Tommy L. S. ;
Menotti, Alessandro ;
Thorpe, Roland J., Jr. ;
Jamrozik, Konrad ;
Calling, Susanna ;
Strand, Bjorn Heine ;
Shipley, Martin J. .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (16) :1720-1728